Document is current

Article History

Accepted: 16 September 2024

First Online: 8 November 2024

Declarations

:

: Supported by the Ministry of Health, Czech Republic—conceptual development of a research organization (Institute for Clinical and Experimental Medicine—IKEM, IN 00023001), RVO VFN 64165, and by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, project no. LX22NPO5104)—Funded by the European Union—Next Generation EU.

: Ondřej Žižka reports no competing interests to declare that are relevant to the content of this article. Martin Haluzík reports having received honoraria for talks and/or consultancy and/or research funding from Eli Lilly, Novo Nordisk, Sanofi, AstraZeneca, Mundipharma, Bristol-Meyers Squibb, Amgen, Boehringer Ingelheim, Janssen, Ypsomed, and Johnson & Johnson. Edward Jude reports having received honoraria and travel grants from Abbott, Astra Zeneca, Boehringer Ingelheim, Lilly, Menanini, Novo Nordisk, and Sanofi.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Ondřej Žižka performed the full literature review and drafted the manuscript. Martin Haluzík and Edward Jude critically revised and contributed to the finalization of the manuscript. All authors read and approved the final manuscript.